Legend raises $200M from private investor after conference leaks PhIII Carvykti data
A day after a leaked data presentation showing positive Phase III results for Legend Biotech’s CAR-T treatment Carvykti, the company said it has raised $200 million in a private stock sale, based on the strength of the data.
Legend is partnered with Johnson & Johnson on the cell therapy, which is already approved as a fifth-line treatment for multiple myeloma. Data from the trial showed that Carvykti was associated with a 74% reduction in the risk of multiple myeloma progression or death.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.